東京大学 · 医学
Hiraku Kumamaru教授の研究室は、医療データを活用した実証的医療研究を柱としており、特にメディカルビッグデータを用いた疾患の疫学的同定や、治療介入の有効性・安全性の比較評価に注力しています。特に、保険請求データを用いた脳卒中や頸動脈内膜剥離術(CEA)のアウトカム評価手法の開発や、虚弱度スコアの国別適用可能性の検討が進んでいます。また、日本国内の多様な医療データベースの特性を的確に把握し、研究目的に最適なデータ選定を支援する研究も展開しています。
Figures are computed from collected data and may differ slightly.
Claims-based algorithms to identify stroke in a contemporary Medicare cohort had high positive predictive value and specificity, supporting their use as outcomes for etiologic and comparative effectiveness studies in similar populations. These inpatient algorithms are unsuitable for estimating stroke incidence because of low sensitivity.
The rate of CEA procedures decreased substantially during 2001 to 2008, as did surgeon past-year case-volume. The postprocedural mortality in Medicare beneficiaries was high compared with trial patients but somewhat improved over time. Those operated by lower past-year case-volume surgeons had increased mortality.
This study was funded by the Patient-Centered Outcomes Research Institute (ME-1309-06274). Kumamaru, Kohsaka, and Miyata are affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, which is a social collaboration department supported by National Clinical Database. The department was formerly supported by endowments from Johnson & Johnson K.K., Nipro, Teijin Pharma, Kaketsuken K.K., St. Jude Medical Japan, Novartis Pharma K.K., Taiho Pharmaceutical, W. L. Gore
The frailty algorithms were applicable to the Japanese system and could contribute to the identifications of enrollees at risk of long-term mortality or LTC use.
The number of databases available for clinico and pharmacoepidemiological research and the proportion of the population they cover are increasing in Japan. The differences in their characteristics mean that the appropriate database must be selected for a particular study purpose.
hdDRSs using historical data with dimension reduction and shrinkage was feasible, and improved confounding adjustment in two studies of newly marketed medications.
Open papers in the app to read, cite, and organize with AI.